Highlights Medivir AB

Equities

MVIR B

SE0020181014

Market Closed - Nasdaq Stockholm Other stock markets 11:29:53 2024-05-14 am EDT			5-day change	1st Jan Change
2.91 ^SEK	-1.36%		-3.00%	+2.11%

May. 07	Medivir Aktiebolag Approves Board Appointments	CI
Apr. 30	Transcript : Medivir AB, Q1 2024 Earnings Call, Apr 30, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medivir AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30	CI
Medivir AB Provides Update from Positive Type C Meeting with the FDA; Preparations for Enhanced Phase 2b in HCC with Fostrox + Lenvima	Apr. 29	CI
FDA Grants Medivir AB´S MIV-711 Rare Pediatric Disease Designation for the Treatment of Legg-Calvé-Perthes Disease	Apr. 25	CI
Medivir Presents Data That Strengthens the Fostrox/Lenvima Combination in Primary Liver Cancer At Easl Liver Cancer Summit	Feb. 22	CI
Medivir AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Medivir AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress	Jan. 18	CI
Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer	Jan. 17	CI
Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers	Dec. 19	CI
Medivir, Lonza Sign Manufacturing Deal for Fostrox	Dec. 13	MT
Medivir AB Agrees with Lonza to Manufacture a Fostrox GMP Campaign, to Be Tested in 2L HCC with Intent to Commercialize Via Accelerated Approval	Dec. 13	CI
Rights Issue: 1 new share @ 2.65 SEK for 1 existing share	Dec. 03	FA
Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC	Nov. 27	CI
Medivir AB to Present Clinical Data at ASCO-GI with Fostrox + Lenvima in HCC and Shares Positive Response from Type D Meeting with FDA	Nov. 13	CI
Medivir AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-27	CI
Medivir AB to Report New and Updated Data from Ongoing Phase 2a HCC Study as Part of Its Third Quarter Report on Friday	23-10-25	CI
Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle	23-10-05	CI
Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima	23-09-04	CI
Medivir AB Announces Patent Application for Fostrox Approval in China	23-06-19	CI
Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima	23-06-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Medivir AB

Equities

MVIR B

SE0020181014

Highlights

Filters